This might be explained by the fact that plasma GFAP might represent an earlier marker than NfL in the AD continuum, and it has been suggested to mediate the relationship between amyloid and tau pathologies in preclinical AD subjects [33]. The gene discussed is GFAP; the disease is amyloidosis.